World Investment Advisors Buys Shares of 16,290 Guardant Health, Inc. $GH

World Investment Advisors purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 16,290 shares of the company’s stock, valued at approximately $1,664,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health during the 4th quarter valued at approximately $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health in the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Guardant Health in the fourth quarter worth approximately $31,000. Elyxium Wealth LLC purchased a new position in Guardant Health in the fourth quarter worth approximately $35,000. Finally, Parallel Advisors LLC grew its position in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

GH has been the topic of a number of research analyst reports. Raymond James Financial restated an “outperform” rating and issued a $129.00 target price on shares of Guardant Health in a research report on Monday, February 23rd. Piper Sandler set a $127.00 price target on Guardant Health in a report on Thursday, May 21st. Royal Bank Of Canada began coverage on Guardant Health in a research report on Thursday, June 11th. They set an “outperform” rating and a $185.00 price objective for the company. Barclays raised their price objective on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Mizuho boosted their price objective on shares of Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $141.95.

Guardant Health Stock Performance

Guardant Health stock opened at $131.78 on Friday. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $135.00. The firm has a 50 day moving average price of $107.23 and a 200 day moving average price of $102.88. The company has a market capitalization of $17.47 billion, a PE ratio of -38.87 and a beta of 1.61.

Insider Activity at Guardant Health

In other news, insider Chris Freeman sold 24,406 shares of Guardant Health stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $118.67, for a total value of $2,896,260.02. Following the completion of the sale, the insider directly owned 60,034 shares of the company’s stock, valued at approximately $7,124,234.78. The trade was a 28.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Helmy Eltoukhy sold 100,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the sale, the chief executive officer owned 2,012,919 shares in the company, valued at $254,231,669.70. This represents a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 449,006 shares of company stock valued at $51,148,938 over the last ninety days. 5.60% of the stock is owned by insiders.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.